A preliminary study on stereotactic ablative brachytherapy for lung metastases from cervical cancer
10.13491/j.issn.1004-714X.2023.05.018
- VernacularTitle:立体定向近距离治疗宫颈癌肺转移灶初探
- Author:
Ying LIU
1
;
Yun ZHOU
2
,
3
;
Xiaoxuan XIE
1
;
Hongrong REN
1
;
Na LI
1
;
Hui HUI
1
;
Wei JIANG
4
Author Information
1. Xuzhou Central Hospital, Xuzhou 221000 China.
2. Xuzhou Central Hospital, Xuzhou 221000 China
3. Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221000 China.
4. Fengxian People’s Hospital, Xuzhou 221700 China.
- Publication Type:OriginalArticles
- Keywords:
Stereotactic ablative brachytherapy;
Lung metastasis;
Clinical benefit rate
- From:
Chinese Journal of Radiological Health
2023;32(5):569-572
- CountryChina
- Language:Chinese
-
Abstract:
Objective To preliminarily study the effectiveness and safety of stereotactic ablative brachytherapy (SABT) for lung metastases from cervical cancer. Methods We analyzed the clinical data of 18 patients with cervical cancer with lung metastasis treated with SABT to compare gross tumor volume (VGTV) and squamous cell carcinoma (SCC) antigen before and after SABT. The clinical benefit rate (CBR) and adverse reactions were recorded. Results After SABT treatment, there were significant decreases in VGTV (t=1.708, P<0.05) and the SCC antigen level (t=1.704, P<0.05). CBR reached 94.4%. Adverse reactions of grades 3-4 did not occur in any patient. Fourteen patients had mild complications, including 1 case of bloody sputum and 1 case of a small pneumothorax. Ten cases developed mild radiation-induced lung injury, with grade 2 radiation pneumonitis in 4 cases. The Karnofsky performance status score and needle depth were not associated with the occurrence of adverse reactions, while the radius of GTV and interstitial lung disease were associated with the occurrence of adverse reactions. Conclusion SABT is a safe and effective alternative to the treatment of lung metastases from cervical cancer.
